Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles New S&P-Led Consortium Targets the Private Markets Data Problem James Comtois Premium RA Capital Preps New Biotech SPAC — With an Eye on China’s Risks Stephen Taub II Communities on Alternative Investments Sponsored by Fidelity Investments